Accordingly, Yap expression was downregulated by cholestyramine treatment, while p21 (cyclin-dependent kinase inhibitor 1) expression was upregulated, indicating that cholestyramine treatment and removal of systemic LPS and bile acids may suppress tumor progression in a specific mechanism (Figure 2E,F). Here, YAP1 is linked to neoplasm.